HER2+ breast cancer: new treatment recommendations for elderly patients

  • Brain E & al.
  • J Geriatr Oncol
  • 21 Jun 2019

  • Oncology guidelines update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The International Society of Geriatric Oncology issued a position paper with recommendations for treating elderly patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
  • Recommendations highlighted the cardiotoxicity of trastuzumab and the higher risk for adverse events associated with the full range of drugs.

Why this matters

  • Guidance has been lacking for the 40% of patients who are elderly and more prone to drug toxicity.
  • Trials often exclude elderly patients despite the fact that they account for a similar percentage of HER2+ tumors (15%-20%).

Study design

  • A task force performed a literature review of Cochrane and PubMed databases to make specific evidence-based treatment recommendations for both fit and frail elderly.
  • Funding: Roche.

Key recommendations

  • Be alert to trastuzumab cardiotoxicity (cardiomyopathy and decline in left ventricular ejection fraction), which increases with age, affecting 2% of young patients and 5% of elderly.
  • Fit elderly can be treated similar to younger patients.
  • In frail elderly with metastatic breast cancer (BCa):
    • Consider avoiding taxanes by substituting with metronomic cyclophosphamide, vinorelbine, or capecitabine, or consider avoiding chemotherapy altogether by prescribing hormonal therapy with hormone-sensitive tumors.
  • In frail elderly with early BCa:
    • Consider trastuzumab without chemotherapy in patients with low-risk tumors.

Limitations

  • Literature search was restricted to studies published after 2000.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit